Lercanidipine Viatris

Lercanidipine, the active ingredient in Lercanidipine Viatris, is a calcium‑channel blocker presented as an oral tablet for oral administration. It produces vasodilation of peripheral arteries, thereby reducing elevated systolic and diastolic blood pressure in adult patients diagnosed with hypertension.

GNH USA supplies Lercanidipine Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing for regulated markets across the European Union and other regions, and adhering to stringent quality standards through a robust supply chain network.

Lercanidipine belongs to the calcium‑channel blocker class and is used to manage high blood pressure.

Hypertension: Lowers systolic and diastolic blood pressure, helping patients achieve recommended target levels.

Lercanidipine may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Headache: mild to moderate intensity, often transient. - Flushing: sensation of warmth and redness, usually temporary. - Peripheral edema: swelling of ankles or feet due to fluid accumulation. - Dizziness: light‑headed feeling, especially when standing quickly. - Tachycardia: increased heart rate without other serious symptoms. - Palpitations: awareness of heart beating irregularly.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure that may cause fainting. - Angioedema: rapid swelling of face, lips, tongue, or throat requiring urgent care. - Myocardial infarction: rare occurrence of heart attack symptoms. - Elevated liver enzymes: indicating possible hepatic stress. - Allergic reactions: rash, itching, or hives that may progress to anaphylaxis. - Chest pain: unexplained discomfort that warrants medical evaluation.

Before initiating therapy, clinicians should consider several safety aspects.

Monitor blood pressure: ensure adequate control without excessive lowering. Assess hepatic function: use caution in patients with liver impairment. Avoid abrupt discontinuation: tapering may be needed to prevent rebound hypertension. Evaluate cardiovascular disease: patients with severe aortic stenosis may be at higher risk. Use cautiously in the elderly: age‑related pharmacokinetic changes may increase sensitivity. Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Lercanidipine can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise plasma concentrations and increase adverse effects. - Concurrent use with other potent antihypertensives: can cause excessive hypotension.

Moderate Interactions (Monitor Closely):\n- CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce therapeutic effect. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may enhance peripheral edema. - Grapefruit juice: can increase drug exposure, requiring dose adjustment or monitoring.